Document 2910
 DOCN  M94A2910
 TI    CMV polyradiculomyelitis in AIDS: 7 cases.
 DT    9412
 AU    Jacomet C; Lebrette MG; De Montfort L; el Amrani M; Gozlan J; Girard PM;
       Rozenbaum W; Hopital Rothschild, Paris, France.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):197 (abstract no. PB0217). Unique
       Identifier : AIDSLINE ICA10/94369665
 AB    OBJECTIVE: To describe features of CMV polyradiculomyelitis. METHODS:
       Retrospective chart analysis of 7 cases. RESULTS: Among 861 AIDS
       patients (pts) from the same unit, 7 cases of CMV polyradiculomyelitis
       were diagnosed from June 1991 to December 1993. It was the first
       manifestation of AIDS in 2/7 cases. Mean duration of previous
       antiretroviral therapy was 16 months. No previous CMV localization had
       previously occurred. Progressive paraparesia developed in all patients
       and was associated with lombar pain in 2/7 patients and with dysuria or
       urinary retention in 5/7 patients. Mean CD4+ T lymphocyte count was
       22/mm3 (3-44). CSF abnormalities were: mean hyperproteinorachia: 1.17
       g/l (0.6-1.56), mean pleocytosis: 398/mm3 (9-1030) with 67%
       polymorphonuclear leukocytes. CSF bacteriological cultures were negative
       but CMV was cultured in 4/5 cases and CMV DNA detected by PCR in 5/5
       cases. Mean duration of ganciclovir therapy (10 mg/kg/d) was 6.5 weeks
       (5-11). Response to therapy (complete: 3 pts, partial: 3 pts and
       unchanged: 1 pt) was related to early intervention. Undertreatment
       analysis of CSF was done in 4 pts: CMV culture negativated in
       Undertreatment analysis of CSF was done in 4 pts: CMV culture
       negativated in 4/4 and PCR in 3/4. Under maintenance ganciclovir therapy
       (5 mg/kg/d), 4/5 pts relapsed after a mean delay of 4.2 weeks and death
       was related to the relapse in 3 patients. CONCLUSION: CMV
       polyradiculomyelitis is a well-defined, recently described disease in
       AIDS pts. CMV PCR appeared highly valuable diagnostic tool. Early
       anti-CMV therapy is required; its best schedule remains to be
       determined.
 DE    AIDS-Related Opportunistic Infections/BLOOD/CEREBROSPINAL FLUID/  DRUG
       THERAPY/*MICROBIOLOGY  Cytomegalovirus/ISOLATION & PURIF
       *Cytomegalovirus Infections/BLOOD/CEREBROSPINAL FLUID/DRUG  THERAPY
       Ganciclovir/THERAPEUTIC USE  Human  Myelitis/BLOOD/CEREBROSPINAL
       FLUID/DRUG THERAPY/*MICROBIOLOGY  Polymerase Chain Reaction
       Polyradiculitis/BLOOD/CEREBROSPINAL FLUID/DRUG THERAPY/  *MICROBIOLOGY
       Recurrence  Retrospective Studies  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).